The world’s most advanced malaria vaccine got the nod Friday from European regulators, despite mixed trial
results, for eventual use in children in African countries plagued by the killer disease.
Dubbed Mosquirix or RTS,S, the drug received a “positive
scientific opinion” from the European Medicines Agency
(EMA) following decades of research and millions of dollars
of investment.
But it has yet to pass a final World Health Organization
(WHO) hurdle, and may not become available before 2017.
Mosquirix is the most clinically-advanced vaccine against
the mosquito-borne disease that infects some 200 million
people and kills about 600,000 every year, more than 75
percent of them children under five.
0 comments:
Post a Comment